Tolerance to Residual Astigmatism in Eyes With Vivity®

Sponsor
Clínica Rementería (Other)
Overall Status
Completed
CT.gov ID
NCT05392998
Collaborator
Alcon Research (Industry)
30
1
8.7
3.4

Study Details

Study Description

Brief Summary

Low amounts of postoperative residual astigmatism may worsen the visual performance of patients implanted with presbyopia- correcting intraocular lenses (IOLs). Although extended depth of focus (EDoF) IOLS have introduced optical improvements, it is important to determine the tolerance of these IOLs to postoperative astigmatism. This is important for an appropriate surgical planning.

Therefore, the aim of this study is to simulate and assess the impact of mild amounts of residual mixed astigmatisms with the axis oriented in different positions (vertical, oblique and horizontal) in eyes implanted with the Vivity® IOL.

Condition or Disease Intervention/Treatment Phase
  • Device: Cataract surgery with Vivity intraocular lens implantation

Detailed Description

Objectives:
  • Primary objective: To describe the tolerance of simulated astigmatism on patients implanted with Vivity at far distance.

  • Secondary objective: To describe the tolerance of simulated astigmatism on patients implanted with Vivity at intermediate distance.

Study Design: Prospective, single arm, descriptive, 3-month follow up.

Patient population: 30 consecutive eyes of 30 patients implanted with Vivity bilaterally with no postoperative complications. The calculation of the required sample size was based on monocular corrected distande visual acuity. A difference of 0.2 logMAR units was assumed to be clinically significant anda standard deviation of 0.05 was anticipated(data obtained from a comparative study between a bifocal and a trifocal IOL: Jonker SM, et al. Journal of Cataract Refract Surg. 2015; 41: 1631-40). Based on these assumptions, with an α of 0.05 and power of 0.8, it was calculated that 25 eyes were required in each group. Due to potential dropouts, a larger sample size has been selected.

Clinical Protocol: All patients fullfilling study criteria will be considered for inclusion three months after surgery. After patient consent, uncorrected distance visual acuity will be measured with an ETDRS chart, followed by subjective refraction (best distance correction). In all cases, mixed astigmatism will be induced with trial lens over the best distance corrected situation (considered the reference situation).

Once the best distance correction is determined, the different visual acuity evaluation procedures for this study will be performed with a Freiburg Acuity Test software package. The software will be run on a separate laptop screen calibrated to be presented at 4 meters. In this procedure, a black Landolt C is presented to the subjects and, among 8 different possibilities, they indicate the orientation of the optotype on a numeric keypad. This test minimizes the observer's bias because the presented optotype depends on the patient´s previous responses. That is, when the observer responds to a certain optotype, the software automatically modifies the size of the next optotype according to parameter estimation by a sequential test method. (7,8) Finally, all serious adverse events will be reported.

Statistical Analysis: Visual acuity values will be expressed as mean and standard deviation. Normal distribution of variables will be assessed using the Kolmogorov- Smirnov test. Pre- and post-operative data of each parameter will be compared by means of the Student's t-test. A repeated measure analysis of variance (ANOVA) will be used to gauge any statistically significant difference of the data within the different simulated situations. Differences are considered to be statistically significant for P value <0.05 (i.e., at the 5% level).

Study Design

Study Type:
Observational
Actual Enrollment :
30 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Tolerance to Residual Astigmatism and Defocus in Eyes With a Non-diffractive Extended Depth of Focus (EDoF) Intraocular Lens
Actual Study Start Date :
Jun 16, 2021
Actual Primary Completion Date :
Mar 9, 2022
Actual Study Completion Date :
Mar 9, 2022

Arms and Interventions

Arm Intervention/Treatment
Vivity patients

The study will include patients >40 years old that undergo routine cataract surgery and implantation of Vivity ®. Exclusion criteria include corneal astigmatism ≥1.0 diopters (D ), amblyopia, previous ocular surgery and presence of ocular pathologies and abnormal iris. Patients with intra- or postoperative complications, with a postoperative best distance corrected visual acuity (BDCVA) < 20/20 and with postoperative refractive astigmatism > 0.50D will be also excluded . Inclusion and exclusion criteria will be assessed by an ophthalmologic examination including refraction, screening for ocular conditions and/or systemic diseases, slit-lamp biomicroscopy and fundus examination.

Device: Cataract surgery with Vivity intraocular lens implantation
Cataract surgery with Vivity intraocular lens implantation

Outcome Measures

Primary Outcome Measures

  1. Distance Against the rule astimatism [Three months after surgery]

    Change from baseline condition in the monocular best corrected distance visual acuity, inducing astigmatism of +0.25-0.50x0*, taking as a reference the subjects' axis

  2. Distance Oblique astigmatism [Three months after surgery]

    Change from baseline condition in the monocular best corrected distance visual acuity, inducing astigmatism of +0.25-0.50x45*, taking as a reference the subjects' axis

  3. Distance With the rule astigmatism [Three months after surgery]

    Change from baseline condition in the monocular best corrected distance visual acuity, inducing astigmatism of +0.25-0.50x90*, taking as a reference the subjects' axis

Secondary Outcome Measures

  1. Intermediate against the rule astigmatism [Three months after surgery]

    Change from baseline condition in the simulated (with -1.50 D) Monocular intermediate visual acuity inducing astigmatism of +0.25-0.50x0*

  2. Intermediate oblique astigmatism [Three months after surgery]

    Change from baseline condition in the simulated (with -1.50 D) Monocular intermediate visual acuity inducing astigmatism of +0.25-0.50x45*

  3. Intermediate with the rule astigmatism [Three months after surgery]

    Change from baseline condition in the simulated (with -1.50 D) Monocular intermediate visual acuity inducing astigmatism of +0.25-0.50x90*

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion Criteria: Patients >40 years old that undergo routine cataract surgery and implantation of Vivity ®.

Exclusion Criteria: corneal astigmatism ≥1.0 diopters (D ), amblyopia, previous ocular surgery and presence of ocular pathologies and abnormal iris. Patients with intra- or postoperative complications, with a postoperative best distance corrected visual acuity (BDCVA) < 20/20 and with postoperative refractive astigmatism > 0.50D will be also excluded .

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clínica Rementería Madrid Spain 28010

Sponsors and Collaborators

  • Clínica Rementería
  • Alcon Research

Investigators

  • Principal Investigator: Laureano Rementeria-Capelo, MD, Clínica Rementería

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Clínica Rementería
ClinicalTrials.gov Identifier:
NCT05392998
Other Study ID Numbers:
  • 21/365-O_P_Viv
First Posted:
May 26, 2022
Last Update Posted:
May 26, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Keywords provided by Clínica Rementería
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 26, 2022